Cis-platinum induction chemotherapy in the multi-modality initial treatment of advanced stage IV carcinoma of the head and neck

Schaefer, Steven David; Middleton, Robert; Reisch, Joan

doi:10.1002/1097-0142(19830615)51:12<2168::aid-cncr2820511204>3.0.co;2-h

Cited by 35 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug was administered intratumorally by Squamous cell 32 12 3 13 2 2 carcinoma Adenocarcinoma 36 21 3 2 3 7 Melanoma 9 -2 5 1 1 Chordoma 2 Cisplatin as a single agent or in combination with other cytotoxic agents has significant activity in many solid tumors, particularly head and neck cancer. [23][24][25][26] There is evidence to support a dose-response relationship for this drug in sensitive tumors. However, attempts to increase dose intensity have been limited by the attendant toxicity, commonly nephrotoxicity, peripheral neuropathy, ototoxicity, myelosuppression, and electrolyte and magnesium wasting.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intratumoral cisplatin/epinephrine‐injectable gel as a palliative treatment for accessible solid tumors: A multicenter pilot study

Burris

Vogel²,

Castro

et al. 1998

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

Intratumoral injections of cisplatin/epinephrine-injectable gel were administered weekly for 4 weeks in 45 patients with malignant tumors of various histologic types. Tumors were located on the skin and subcutaneous tissue primarily of the head, neck, and trunk, and on the tongue, oral pharynx, and esophagus. Patients were not candidates for surgery, radiation, or systemic chemotherapy. Each of the treated tumors (n = 82) was evaluated 2, 4, 8, and 12 weeks after the final injection. The initial dose of cisplatin was 1 mg/cm3 tumor volume, with escalation to 6 mg/cm3 allowed, depending on observed toxicities. The mean cumulative dose per patient for the four treatments ranged from 0.56 to 380 mg cisplatin. No dose-limiting cisplatin-related toxicities, such as nephrotoxicity, neurotoxicity, or ototoxicity, were observed. The overall objective tumor response rate was 50% (41 of 82), with 40% (33 of 82) complete responses and a median response duration of 160 days. Complete responses for adenocarcinoma and squamous cell carcinoma were 58% (21 of 36) and 38% (12 of 32), respectively. These results justified further clinical trials to evaluate the role of local chemotherapy with intratumoral cisplatin/epinephrine-injectable gel in the palliative treatment of patients with selected accessible solid tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Cisplatin as a single agent or in combination with other cytotoxic agents has significant activity in many solid tumors, particularly head and neck cancer 23‐26 . There is evidence to support a dose‐response relationship for this drug in sensitive tumors.…”

Section: Discussionmentioning

confidence: 99%

Intratumoral cisplatin/epinephrine‐injectable gel as a palliative treatment for accessible solid tumors: A multicenter pilot study

Burris

Vogel²,

Castro

et al. 1998

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

show abstract

“…Distant metastases developed in 10–30%. Furthermore, radical surgery frequently has devastating effects on cosmesis, speech, and swallowing 2–8…”

mentioning

confidence: 99%

Induction paclitaxel and carboplatin for patients with head and neck carcinoma

Dunphy

Dunleavy

Harrison

et al. 2001

Cancer

View full text Add to dashboard Cite

BACKGROUND After standard therapy for advanced head and neck carcinoma, 5‐year survival rate is less than 50%. Our purpose was to develop a new treatment for advanced head and neck carcinoma by using preoperative chemotherapy. Long term efficacy and toxicity of induction paclitaxel and carboplatin is reported here. METHODS Between 1994 and 1999, 62 consecutive patients with newly diagnosed head and neck carcinoma were treated with paclitaxel and carboplatin induction chemotherapy. Chemotherapy was administered every 21 days with 3 courses of paclitaxel (150–265 mg/m2) and carboplatin at a dose calculated using the Calvert formula area under the curve of 7.5. Patients who achieved complete or partial response at the primary received definitive radiation to the primary tumor and those with lymph node disease received neck dissection followed by radiation to the regional lymph nodes. Nonresponders received standard resection of primary tumor and draining lymph node basin followed by radiation. RESULTS Sixty‐two consecutive patients were treated. Seventy‐four percent had Stage IV (according to the 5th edition of American Joint Committee on Cancer Staging manual) disease. The median duration of follow‐up from initiation of chemotherapy was 64 weeks (range, 1–272 weeks). Overall complete plus partial response rate was 41 of 62 (66%). Responses were observed at all anatomic sites: oropharynx 20 of 33 (61%); hypopharynx 8 of 12 (67%); and larynx 13 of 17 (76%). Kaplan–Meier estimates of overall survival (OS), at 230 weeks, were significantly better in Stage IV oropharynx/hypopharynx responders than nonresponders (55% vs. 27%; P = 0.04). Of the variables evaluated in multivariate models, response at the primary tumor and lymph nodes were associated with improved disease free survival and OS. Organ preservation was achieved in 28 of 62 (45%) of patients at all anatomic sites: oropharynx 39%, hypopharynx 42%, larynx 59%. Seventeen of 28 (61%) patients had their primary organ site preserved for a mean duration of 78 weeks (range, 13–238 weeks). CONCLUSIONS Induction paclitaxel and carboplatin was well tolerated. The response rate was encouraging considering most patients were Stage IV. Chemotherapy response identified a group with improved prognosis. Organ preservation was possible at all anatomic sites. Cancer 2001;91:940–8. © 2001 American Cancer Society.

show abstract

Computed Tomography of Upper Aerodigestive Tract Squamous Cell Carcinoma: Assessment Following Induction Chemotherapy

Schaefer

Merkel

Burns³

et al. 1984

Archives of Otolaryngology - Head and Neck Surgery

View full text Add to dashboard Cite

\s=b\ One hundred forty-seven previously untreated patients with stage III or IV upper aerodigestive tract squamous cell carcinomas were examined by computed tomography (CT) prior to treatment. Computed tomography was used to observe the tumor response in 72 patients receiving induction chemotherapy (100 mg/sq m of cisplatin on days 1 and 21 and 135 mg/sq m of bleomycin sulfate on days 3 through 10). The CT findings in ten patients were correlated with serial histologic examination of the operative specimens. Our study indicates that CT is useful in following tumor response to chemotherapy, provided the physician is aware of the limitations of scanning as outlined herein.

show abstract

Cis-platinum induction chemotherapy in the multi-modality initial treatment of advanced stage IV carcinoma of the head and neck

Cited by 35 publications

References 9 publications

Intratumoral cisplatin/epinephrine‐injectable gel as a palliative treatment for accessible solid tumors: A multicenter pilot study

Intratumoral cisplatin/epinephrine‐injectable gel as a palliative treatment for accessible solid tumors: A multicenter pilot study

Induction paclitaxel and carboplatin for patients with head and neck carcinoma

Computed Tomography of Upper Aerodigestive Tract Squamous Cell Carcinoma: Assessment Following Induction Chemotherapy

Contact Info

Product

Resources

About